ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Association of Euthyroid Thyroid Hormone Levels with Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The frequency of nonalcolic fatty liver disease (NAFLD), a major health issue that affects people all over the world, has been rising recently. Numerous studies have demonstrated the tight connection between NAFLD and thyroid function. In this study, we aimed to evaluate the relationship between thyroid function tests and the degree of liver steatosis in patients with biopsy proven NAFLD. Patients and Methods: We retrospectively evaluated data of living donor applicants who received liver biopsies. Three hundred sixty seven patients were included in the study. According to the liver biopsy results, the patients were divided into two groups; 227 patients biopsy-proven NAFLD and 145 control subjects without NAFLD. Demographic, anthropometric and laboratory parameters were compared between two groups. Results: All groups thyroid function tests fall within the normal range. However, in patients with NAFLD, serum FT3 and FT4 levels were significantly higher than control group. In addition negative relationship was found between the levels of FT3, FT4, and the stage of NAFLD. In patients with NAFLD, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglyceride, total cholesterol levels, homeostasis model assessment of insulin resistance (HOMA-IR), body mass index were significantly high. Conclusion: In this retrospective study, we showed that in patients with NAFLD, serum FT3 and FT4 levels were significantly lower than the control group. Our findings support that low levels of serum FT3 and FT4 might be a risk factor for liver steatosis in euthyroid patients with NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.